Table 1 CXCL9 expression in human tumor biopsies treated ex vivo with galectin antagonists.

From: Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration

Tumor code

Tumor type

Untreated (*)

LacNAc

IFNγ

IFNγ + galectins antagonists

     

LacNAc

GM-CT-01

αGal3 mIgG1

αGal3 ratIgG

13-121

Neuroendocrina

1 (3)

51

317

281

N/A

N/A

N/A

14-031

Adenocarcinoma

1 (12)

1

5

2

2

N/A

N/A

13-212

Adenocarcinoma

1 (33)

15

7

82

N/A

N/A

N/A

14-286

Renal carcinoma

1 (67)

N/A

36

91

 

242

N/A

14-581

Pancreatic carcinoma

1 (77)

29

112

392

251

31

8

13-248

Adenocarcinoma

1 (78)

2

1

3

N/A

N/A

N/A

13-480

Adenocarcinoma

1 (89)

0

2

73

12

N/A

N/A

15-426

Uterine carcinoma

1 (139)

2

2

5

10

1

1

12-477

Adenocarcinoma

1 (168)

1

1

2

N/A

N/A

N/A

13-298

Adenoma

1 (193)

2

2

5

N/A

N/A

N/A

13-568

Hepatoadenoma

1 (268)

1

5

11

9

N/A

N/A

LB-3422

Melanoma

1 (379)

0

1

16

2

N/A

N/A

14-063

Adenocarcinoma

1 (399)

5

7

14

14

N/A

N/A

14-583

Adenocarcinoma

1 (406)

N/A

2

7

2

4

8

15-427

Adenocarcinoma

1 (489)

1

3

3

2

3

2

15-228

Sarcoma

1 (972)

2

98

193

195

116

138

14-187

Rectal adenocarcinoma

1 (1065)

1

1

5

3

N/A

N/A

13-420

Lymphoma B diffuse

1 (1278)

2

2

2

N/A

N/A

N/A

14-526

Renal carcinoma

1 (1287)

2

3

3

3

1

2

13-454

Adenocarcinoma

1 (1287)

1

2

1

N/A

N/A

N/A

12-529

Hepatoblastoma

1 (1628)

4

3

8

N/A

N/A

N/A

14-239

Renal carcinoma

1 (3321)

1

2

2

1

1

N/A

12-549

Leiomyoma

1 (8056)

14

5

33

40

N/A

N/A

  1. Fold induction CXCL9 values using HPRT-1 as a reference gene and with respect to the untreated condition (2−ΔΔCt). For the untreated condition, CXCL9 mRNA levels normalized to HPRT-1 (103 × 2−ΔCt) are indicated in brackets. Human biopsies were treated for 6 h with IFNγ (50 ng ml−1), LacNAc (10 mM), GM-CT-01 (100 μg ml−1), and/or anti-galectin-3 antibodies (10 μg ml−1)
  2. N/A no available data
Back to article page